{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:43:45Z","timestamp":1782791025911,"version":"3.54.5"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020013","name":"NIHR Leicester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large, high-quality, real-world studies on the efficacy of weight-lowering interventions, including the glucagon-like peptide-1\u2013based therapies semaglutide and tirzepatide, as well as bariatric surgery (BS). This retrospective cohort study evaluates these interventions on cardiorenal outcomes and mortality using health records from TriNetX US Collaborative Network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three cohorts with T2DM and CKD living with overweight or obesity, prescribed semaglutide or tirzepatide, or with a BS procedure were propensity-score matched with a cohort receiving dipeptidyl peptidase 4 inhibitors (DPP4i, weight-neutral control). We investigated the hazard ratio (HR) of: (i) end-stage renal disease (ESRD); (ii) myocardial infarction (MI); (iii) stroke; and (iv) all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cohorts included 17\u2009749 (semaglutide, age 64.1\u00a0\u00b1\u00a010.9 years, 57.4% female), 4211 (tirzepatide, 63.7\u00a0\u00b1\u00a010.8, 58.1%) and 2603 (BS, 56.1\u00a0\u00b1\u00a011.2, 74.1%) patients. Compared with DPP4i, semaglutide reduced the risk of ESRD [HR 0.78 (95% confidence interval 0.71 to 0.85)], while tirzepatide showed a reduction of 42% (0.0.58, 0.45 to 0.75). BS lowered ESRD risk (0.79, 0.67 to 0.92). Semaglutide reduced MI (0.80, 0.72 to 0.88) and stroke (0.85, 0.77 to 0.95) risk, while tirzepatide lowered MI and stroke by 24%. BS was associated with reduced MI (0.45, 0.35 to 0.58) and stroke (0.57, 0.44 to 0.74) risk. All-cause mortality risk was reduced by semaglutide (0.64, 0.59 to 0.70), tirzepatide (0.47, 0.35 to 0.63) and BS (0.68, 0.57 to 0.81).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using a real-world dataset, semaglutide, tirzepatide and BS\u2014interventions shown to elicit weight loss and improve glycaemic control\u2014have a myriad of benefits on cardio-renal outcomes and mortality, supporting their use as disease-modifying therapy options in T2DM and CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf258","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:23:03Z","timestamp":1764768183000},"page":"1262-1273","source":"Crossref","is-referenced-by-count":2,"title":["Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-7752","authenticated-orcid":false,"given":"Thomas J","family":"Wilkinson","sequence":"first","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldney","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yates","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Henson","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Centre , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Webb","sequence":"additional","affiliation":[{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]},{"name":"University of Hospitals Leicester NHS Trust , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-1515","authenticated-orcid":false,"given":"Dimitris","family":"Papamargaritis","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Centre , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J","family":"Davies","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester Diabetes Centre , Leicester ,","place":["UK"]},{"name":"Leicester Diabetes Centre, Leicester General Hospital, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Centre , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026062922471031300_bib1","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.3390\/jcm12226984","article-title":"Cardiovascular disease in diabetes and chronic kidney disease","volume":"12","author":"Swamy","year":"2023","journal-title":"J Clin Med"},{"key":"2026062922471031300_bib2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2026062922471031300_bib3","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026062922471031300_bib4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026062922471031300_bib5","first-page":"59","article-title":"Obesity and diabetic kidney disease","volume":"97","author":"Maric-Bilkan","year":"2013","journal-title":"Med Clin"},{"key":"2026062922471031300_bib6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13300-023-01384-7","article-title":"The association between obesity and the 5-year prevalence of morbidity and mortality among adults with type 2 diabetes","volume":"14","author":"Boye","year":"2023","journal-title":"Diabetes Ther"},{"key":"2026062922471031300_bib7","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.7861\/clinmed.2021-0370","article-title":"Managing obesity in people with type 2 diabetes","volume":"21","author":"Grant","year":"2021","journal-title":"Clin Med"},{"key":"2026062922471031300_bib8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/nep.13958","article-title":"Improvement of kidney function in patients with chronic kidney disease and severe obesity after bariatric surgery: a systematic review and meta-analysis","volume":"27","author":"Lee","year":"2022","journal-title":"Nephrology"},{"key":"2026062922471031300_bib9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3949\/ccjm.77a.09135","article-title":"Bariatric surgery for type 2 diabetes: weighing the impact for obese patients","volume":"77","author":"Kashyap","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"2026062922471031300_bib10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S2213-8587(14)70020-8","article-title":"Bariatric surgery","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922471031300_bib11","doi-asserted-by":"publisher","first-page":"e0285197","DOI":"10.1371\/journal.pone.0285197","article-title":"Weight loss efficiency and safety of tirzepatide: a systematic review","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"2026062922471031300_bib12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026062922471031300_bib13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CRD.0000000000000515","article-title":"Tirzepatide for weight loss: can medical therapy \u201coutweigh\u201d bariatric surgery?","volume":"31","author":"Novograd","year":"2023","journal-title":"Cardiol Rev"},{"key":"2026062922471031300_bib14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922471031300_bib15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922471031300_bib16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib17","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"2026062922471031300_bib18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib20","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026062922471031300_bib21","doi-asserted-by":"publisher","first-page":"17562864241281904","DOI":"10.1177\/17562864241281903","article-title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP\/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","volume":"17","author":"Stefanou","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"2026062922471031300_bib22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922471031300_bib23","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1681\/ASN.0000000764","article-title":"Kidney parameters with tirzepatide in obesity with or without type 2 diabetes","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026062922471031300_bib24","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.2147\/DMSO.S473319","article-title":"Tirzepatide prescribing practices and efficacy in patients with diabetes and chronic kidney disease at a large tertiary care center in the United States","volume":"17","author":"Kosaraju","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026062922471031300_bib25","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/ndt\/gfaf069","article-title":"How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the diabesity working group of the ERA","volume":"40","author":"Morales","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922471031300_bib26","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026062922471031300_bib27","doi-asserted-by":"publisher","first-page":"e082071","DOI":"10.1136\/bmj-2024-082071","article-title":"RAPID RECOMMENDATIONS Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline","volume":"390","author":"Agarwal","year":"2025","journal-title":"BMJ"},{"key":"2026062922471031300_bib28","doi-asserted-by":"publisher","first-page":"e111543","DOI":"10.1371\/journal.pone.0111543","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"key":"2026062922471031300_bib29","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/JAMIAOPEN\/OOAD035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2026062922471031300_bib30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib31","doi-asserted-by":"publisher","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026062922471031300_bib32","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.2337\/dc11-s229","article-title":"DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors","volume":"34","author":"Harashima","year":"2011","journal-title":"Diabetes Care"},{"key":"2026062922471031300_bib33","doi-asserted-by":"publisher","first-page":"e30535","DOI":"10.7759\/CUREUS.30535","article-title":"Chronic kidney disease: its relationship with obesity","volume":"14","author":"Prasad","year":"2022","journal-title":"Cureus"},{"key":"2026062922471031300_bib34","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"2026062922471031300_bib35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"key":"2026062922471031300_bib36","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026062922471031300_bib37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/dtb.2023.000007","article-title":"Semaglutide: a new drug for the treatment of obesity","volume":"61","author":"Lexchin","year":"2023","journal-title":"Drug Ther Bull"},{"key":"2026062922471031300_bib38","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/ckj\/sfaa266","article-title":"Renoprotective role of bariatric surgery in patients with established chronic kidney disease","volume":"14","author":"Morales","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026062922471031300_bib39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026062922471031300_bib40","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/biomedicines10071661","article-title":"Nephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease","volume":"10","author":"Dalb\u00f8ge","year":"2022","journal-title":"Biomedicines"},{"key":"2026062922471031300_bib41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","article-title":"Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future","volume":"84","author":"Caruso","year":"2024","journal-title":"Endocrine"},{"key":"2026062922471031300_bib42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026062922471031300_bib43","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026062922471031300_bib45","article-title":"Study details | a study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes | ClinicalTrials.gov"},{"key":"2026062922471031300_bib46","doi-asserted-by":"publisher","first-page":"e2235003","DOI":"10.1001\/jamanetworkopen.2022.35003","article-title":"Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease","volume":"5","author":"Rustgi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026062922471031300_bib47","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/heartjnl-2012-301778","article-title":"Bariatric surgery and cardiovascular outcomes: a systematic review","volume":"98","author":"Vest","year":"2012","journal-title":"Heart"},{"key":"2026062922471031300_bib48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"2026062922471031300_bib49","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026062922471031300_bib50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Int Med"},{"key":"2026062922471031300_bib51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"key":"2026062922471031300_bib52","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026062922471031300_bib53","doi-asserted-by":"publisher","first-page":"F137","DOI":"10.1152\/ajprenal.00064.2012","article-title":"Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat","volume":"304","author":"Thomson","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026062922471031300_bib54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026062922471031300_bib55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026062922471031300_bib56","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1111\/DOM.70123;PAGEGROUP:STRING:PUBLICATION","article-title":"Sex differences in the efficacy of GLP-1 receptor agonists: a systematic review and meta-analysis of cardiovascular and renal outcome trials","volume":"27","author":"Siddiqui","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026062922471031300_bib57","doi-asserted-by":"publisher","first-page":"e2530952","DOI":"10.1001\/jamanetworkopen.2025.30952","article-title":"GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026062922471031300_bib58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-025-04378-8","article-title":"Kidney outcomes after bariatric surgery: a population-based cohort study","volume":"26","author":"S\u00f8rensen","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026062922471031300_bib59","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1634\/theoncologist.2018-0141","article-title":"How do the accrual pattern and follow-up duration affect the hazard ratio estimate when the proportional hazards assumption is violated?","volume":"24","author":"Horiguchi","year":"2019","journal-title":"Oncologist"},{"key":"2026062922471031300_bib60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/VHRM.S10952","article-title":"Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience","volume":"6","author":"Foley","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"2026062922471031300_bib61","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.120.049514","article-title":"Challenges of cardio-kidney composite outcomes in large-scale clinical trials","volume":"143","author":"Patel","year":"2021","journal-title":"Circulation"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf258\/65742371\/gfaf258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1262\/65742371\/gfaf258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1262\/65742371\/gfaf258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:47:21Z","timestamp":1782787641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/7\/1262\/8365542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf258","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,4]]}}}